Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Brain Arteriovenous Malformation
NCT02314377Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Jun 2016
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in brain arteriovenous malformation (AVM), sponsored by University of California, San Francisco. Primary endpoint: Change in AVM volume from pre-treatment MRI at 52 weeks. Started Jun 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
brain arteriovenous malformation (AVM)
Beyond the preview
Go deeper on NCT02314377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314377.